Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Kromek Group undergoing a commercial transformation as forecasts 40% growth in revenues

The company, headquartered in Durham, is now reaping the rewards of two years hard work as it is delivering the orders it has generated in that time
Kromek Group undergoing a commercial transformation as forecasts 40% growth in revenues
The company's radiation detection units have been shipped in bulk to the US

Kromek Group PLC (LON:KMK), the maker of radiation detection technology used in medical devices and security, said it is seeing a “step change” across the business with revenues expected grow 40% in the current year – in line with previous forecasts.

The company, headquartered in Durham, is now reaping the rewards of two years hard work as it is delivering the orders it has generated in that time.

In medical imaging, where its technology is incorporated into diagnostic systems, it has secured a £9.8mln (US$12.6mln), five-year contract along with a number of other deals, while the security operation has hammered down a separate five-year deal, this time worth least £2.4mln (US$3.1mln).

WATCH:'This is the year Kromek turns a financial corner' - CEO Dr Arnab Basu

Nuclear detection doing well

Kromek’s nuclear detection business, meanwhile, has delivered 10,000 of its D3S radiation units to the US Defense Research Projects Agency’s Sigma project, which is there to head off the threat of nuclear terrorism. The order is a huge tick in the box of the company’s devices, analysts said.

In January it raised £21mln from investors which has allowed it to tap into the huge market opportunities and to invest in research and development, which keeps the company at the cutting edge of radiation technology.

In the year ended April 30 Kromek generated revenues of £8.7mln, up from £8.3mln. As might be expected from a business setting out on the commercial phase of its development, it was loss-making – to the tune of £1.5mln.

High performance radiation detection

The company is the developer of high performance radiation detection products based on cadmium zinc telluride and other advanced technologies.

Using its core platforms, Kromek designs, develops and produces x-ray and gamma photon imaging and radiation detection products for the medical, security screening and nuclear markets.

They provide high resolution information on material composition and structure.

This means they can be used in many applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

Vertically integrated

Kromek operates a vertically integrated technology. What this means practically is it offers customers core technology components as well finished products such detectors, including software, electronics and application specific integrated circuits.

While based in the north-east, the business, which employs 100, has operations in California and Pennsylvania and sells internationally through distributors and direct to manufacturers.


View full KMK profile View Profile

Kromek Group PLC Timeline

Related Articles

Male model
July 09 2018
Clothes maketh the man ... and the chances are, those clothes were bought from a website that uses ATTRQT's technology
Video game media with player
August 21 2018
Analysts at German bank Berenberg have upped their target price for the firm to 2,150p from 2,060p, saying the company's market is expected to "outgrow the video game segment"
Big lorry
August 25 2018
"Trains, planes and automobiles" - it's the name of a classic John Hughes film but it might also be a good title for the story of Seeing Machines

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use